Print

TYRX Receives Health Canada Approval  
10/4/2012 6:55:49 AM

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- TYRX, Inc., the leader in the commercialization of implantable medical devices intended to help reduce surgical site infections, announced today that it has received a license from Health Canada to market its AIGISRx Antibacterial Envelope. The AIGISRx Envelope is specifically designed to stabilize pacemakers and implantable defibrillators while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation.

“We are very excited about bringing the AIGISRx technology to the Canadian market in order to help reduce patient morbidity, mortality, and health care system costs related to CIED infections,” said Robert White, TYRX President and Chief Executive Officer.

The AIGISRx Envelope is primarily intended to hold the pacemaker or defibrillator (ICD) securely in place in order to provide a stable environment when implanted in the body. Additionally, the AIGISRx contains the antimicrobial agents rifampin and minocycline, which are released over a 7 to 10 day period, in order to help provide protection from microbial colonization of the device during surgical implantation.

The AIGISRx Envelope is FDA-cleared in the United States and has been implanted in well over 25,000 patients since its commercial release.

TYRX is currently evaluating distribution partners for its launch of the AIGISRx Envelope into the Canadian market and will be exhibiting at the Canadian Cardiovascular Congress in Toronto (October 27-30).

About TYRX, Inc.

TYRX, Inc. commercializes innovative, implantable combination drug+device products focused on infection control, including the AIGISRx® Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including “superbugs” such as methicillin-resistant S. aureus (MRSA).*

For more information, please visit www.TYRX.com or www.HeartDeviceInfection.com.

*Data on file at TYRX and published in PACE.2009; 32(7):898-907.

Contact:

TYRX, Inc.

Robert White, 732-246-8676

President and Chief Executive Officer

info@TYRX.com


//-->